Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center

Fig. 1

Survival outcomes after a median follow-up of 15.4 months. A Median progression-free survival time in all patients was not reached, 1-year PFS was 81% in SMART group and 84% in SMART–START group. B Median overall survival time in all patients was not reached, 1-year overall survival was 89% in SMART group and 91% in SMART–START group

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us